Company Filing History:
2 out of 74 
1 out of 61 
1 out of 8 Years Active: 2019-2021
Title: Innovations of Claudia Duehrkop-Sisewitsch in Ischemia-Reperfusion Injury
Introduction
Claudia Duehrkop-Sisewitsch is a notable inventor based in Knivsta, Sweden, recognized for her contributions to the medical field through her innovative patents. With a focus on treatments related to ischemia-reperfusion injury, she has made significant strides in her area of expertise, holding two patents that underline her commitment to advancing medical science.
Latest Patents
Claudia's latest invention is centered on the treatment and prevention of remote ischemia-reperfusion injury (IRI). Her patent details a novel contact activation system inhibitor, primarily C1INH, which is designed for use in the treatment and/or prevention of IRI. The proposed system aims to administer this contact activation system inhibitor to individuals at risk of such injuries, representing a meaningful advancement in therapeutic options for affected patients.
Career Highlights
Throughout her career, Claudia has worked with prestigious organizations, including CSL Behring GmbH and Universität Bern. These experiences have provided her with a solid foundation in research and development, enabling her to innovate in the challenging field of ischemia-reperfusion injuries. Her work has not only enhanced her knowledge but has also contributed to her success as an inventor.
Collaborations
Claudia has collaborated with renowned professionals in the field, including Rolf Spirig and Sylvia Miescher. Working alongside these esteemed colleagues has enriched her research endeavors, allowing her to expand the impact of her inventions and patents in the medical community.
Conclusion
Claudia Duehrkop-Sisewitsch exemplifies the spirit of innovation within the medical field. Her two patents focusing on the treatment and prevention of remote ischemia-reperfusion injury highlight her dedication to improving patient care and outcomes. As she continues her work, her contributions are sure to influence future advancements in medical treatments.